ST天圣(002872) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥106,834,882.76, a decrease of 63.21% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥27,356,755.05, representing a 46.16% increase in losses year-over-year[3]. - Total operating revenue for Q3 2021 was CNY 601.84 million, a decrease of 33.2% compared to CNY 900.11 million in the same period last year[29]. - Net loss for Q3 2021 was CNY 68.38 million, compared to a net loss of CNY 125.83 million in Q3 2020, representing a 45.6% improvement[30]. - The company's gross profit margin for Q3 2021 was approximately 38.4%, compared to 28.0% in the same period last year[29]. - The basic and diluted earnings per share for Q3 2021 were both CNY -0.2133, an improvement from CNY -0.3752 in Q3 2020[31]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥35,213,819.19, a decrease of 126.40% year-to-date[3]. - The total cash inflow from operating activities was approximately CNY 734.80 million, a decrease from CNY 1,292.58 million in the previous year, reflecting a decline of about 43%[34]. - The net cash outflow from operating activities was CNY -35.21 million, compared to a net inflow of CNY 133.40 million in the same period last year[34]. - The cash inflow from financing activities was CNY 220.06 million, while the cash outflow was CNY 270.77 million, resulting in a net cash outflow of CNY -50.71 million[35]. - The ending balance of cash and cash equivalents was CNY 136.05 million, down from CNY 274.43 million at the end of the previous year[35]. - The company reported a significant increase in cash paid for purchasing goods and services, totaling CNY 401.33 million, compared to CNY 679.37 million in the previous year[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,088,305,645.94, down 15.29% from the end of the previous year[4]. - The total assets decreased to CNY 3.09 billion in Q3 2021 from CNY 3.65 billion in the previous year, a decline of 15.4%[27]. - Total liabilities decreased to CNY 808.65 million in Q3 2021, down 35.6% from CNY 1.26 billion in Q3 2020[27]. - The company reported a significant increase in other receivables, rising from 59,199,305.44 RMB at the end of 2020 to 332,453,945.64 RMB by September 30, 2021[25]. - The company experienced a 203.49% increase in accounts receivable, attributed to delays in endorsing received notes[9]. Inventory and Costs - The company’s inventory decreased by 59.97% as a result of the sale of a subsidiary[9]. - The company’s inventory decreased from 288,579,821.77 RMB at the end of 2020 to 121,294,721.96 RMB by September 30, 2021, a decline of approximately 57.9%[25]. - The company’s operating costs decreased by 42.97%, primarily due to the reduction in the scope of consolidation after the sale of a subsidiary[12]. - Total operating costs for Q3 2021 were CNY 694.14 million, down 31.4% from CNY 1,012.71 million year-on-year[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,831[15]. - The largest shareholder, Liu Qun, holds 32.89% of the shares, amounting to 104,590,532 shares, with 35,000,000 shares pledged[15]. - The company has 10 major shareholders, with the first and eighth largest shareholders being brothers, indicating potential related party transactions[16]. Legal and Compliance Issues - The company is currently involved in a legal case regarding bribery, with a first-instance judgment imposing fines totaling 3.8 million RMB[17]. - The company did not conduct an audit for the third quarter report[37]. - The report indicates that the company has not made any adjustments related to the new leasing standards for the current year[36]. Investment and Restructuring - The company reported a significant increase in investment income of 13,597.49% due to the sale of a subsidiary[13]. - The company completed a major asset restructuring by selling 51% of the equity in Chongqing Pharmaceutical Group Changsheng Pharmaceutical Co., Ltd. on April 29, 2021[22]. - The company’s goodwill decreased by 31.53% following the sale of a subsidiary[9]. - The company’s financial expenses decreased by 87.81% due to the recovery of funds from the former chairman[13]. - Liu Qun has repaid a total of 12,147.4926 million RMB of misappropriated funds as of April 8, 2021[21].